Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
1.
Sci Rep ; 11(1): 9023, 2021 04 27.
Article in English | MEDLINE | ID: mdl-33907251

ABSTRACT

Despite several studies designed to evaluate the efficacy of chloroquine and hydroxychloroquine in the treatment of coronavirus disease 2019 (COVID-19), there is still doubt about the effects of these drugs, especially in patients with severe forms of the disease. This randomized, open-label, controlled, phase III trial assessed the efficacy of chloroquine or hydroxychloroquine for five days in combination with standard care compared to standard care alone in patients hospitalized with severe COVID-19. Chloroquine 450 mg BID on day 1 and 450 mg once daily from days 2 to 5 or hydroxychloroquine 400 mg BID on day 1 and 400 mg once daily from days 2 to 5 were administered in the intervention group. Patients were enrolled from April 16 to August 06, 2020, in 6 hospitals in southern Brazil. The primary outcome was the clinical status measured on day 14 after randomization with a 9-point ordinal scale. The main secondary outcomes were all-cause mortality; invasive mechanical ventilation use; the incidence of acute renal dysfunction in 28 days; and the clinical status of patients on days 5, 7, 10 and 28. All patients with a positive RT-PCR result for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were analyzed (modified intention to treat (mITT) population). Arrythmias and cardiovascular complications were assessed as safety outcomes. A total of 105 patients were enrolled and followed for 28 days. The trial was stopped before reaching the planned sample size due to harmful effects. Patients in the intervention group had a worse clinical outcome on the 14th day (odds ratio (OR) 2.45 [1.17 to 4.93], p = 0.016) and on the 28th day (OR 2.47 [1.15 to 5.30], p = 0.020). Moreover, the intervention group had higher incidences of invasive mechanical ventilation use (risk ratio (RR) 2.15 [1.05 to 4.40], p = 0.030) and severe renal dysfunction (KDIGO stage 3) (RR 2.24 [1.01 to 4.99], p = 0.042) until the 28th day of follow-up. No significant arrythmia was noted. In patients with severe COVID-19, the use of chloroquine/hydroxychloroquine added to standard treatment resulted in a significant worsening of clinical status, an increased risk of renal dysfunction and an increased need for invasive mechanical ventilation.Trial Registration: ClinicalTrials.gov, NCT04420247. Registered 09 June 2020-Retrospectively registered, https://www.clinicaltrials.gov/ct2/show/study/NCT04420247 .


Subject(s)
Antiviral Agents/therapeutic use , COVID-19 Drug Treatment , Chloroquine/therapeutic use , Hydroxychloroquine/therapeutic use , Adult , COVID-19/mortality , COVID-19/pathology , COVID-19/virology , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , SARS-CoV-2/isolation & purification , Survival Rate , Treatment Outcome
2.
Silva Júnior, João Manoel; Chaves, Renato Carneiro de Freitas; Corrêa, Thiago Domingos; Assunção, Murillo Santucci Cesar de; Katayama, Henrique Tadashi; Bosso, Fabio Eduardo; Amendola, Cristina Prata; Serpa Neto, Ary; Hospital das ClínicasMalbouisson, Luiz Marcelo Sá; Oliveira, Neymar Elias de; Veiga, Viviane Cordeiro; Rojas, Salomón Soriano Ordinola; Postalli, Natalia Fioravante; Alvarisa, Thais Kawagoe; Hospital das ClínicasLucena, Bruno Melo Nobrega de; Hospital das ClínicasOliveira, Raphael Augusto Gomes de; Sanches, Luciana Coelho; Silva, Ulysses Vasconcellos de Andrade e; Nassar Junior, Antonio Paulo; Réa-Neto, Álvaro; Amaral, Alexandre; Teles, José Mário; Freitas, Flávio Geraldo Rezende de; Bafi, Antônio Tonete; Pacheco, Eduardo Souza; Ramos, Fernando José; Vieira Júnior, José Mauro; Pereira, Maria Augusta Santos Rahe; Schwerz, Fábio Sartori; Menezes, Giovanna Padoa de; Magalhães, Danielle Dourado; Castro, Cristine Pilati Pileggi; Henrich, Sabrina Frighetto; Toledo, Diogo Oliveira; Parra, Bruna Fernanda Camargo Silva; Dias, Fernando Suparregui; Zerman, Luiza; Formolo, Fernanda; Nobrega, Marciano de Sousa; Piras, Claudio; Piras, Stéphanie de Barros; Conti, Rodrigo; Bittencourt, Paulo Lisboa; DOliveira, Ricardo Azevedo Cruz; Estrela, André Ricardo de Oliveira; Oliveira, Mirella Cristine de; Reese, Fernanda Baeumle; Motta Júnior, Jarbas da Silva; Câmara, Bruna Martins Dzivielevski da; David-João, Paula Geraldes; Tannous, Luana Alves; Chaiben, Viviane Bernardes de Oliveira; Miranda, Lorena Macedo Araújo; Brasil, José Arthur dos Santos; Deucher, Rafael Alexandre de Oliveira; Ferreira, Marcos Henrique Borges; Vilela, Denner Luiz; Almeida, Guilherme Cincinato de; Nedel, Wagner Luis; Passos, Matheus Golenia dos; Marin, Luiz Gustavo; Oliveira Filho, Wilson de; Coutinho, Raoni Machado; Oliveira, Michele Cristina Lima de; Friedman, Gilberto; Meregalli, André; Höher, Jorge Amilton; Soares, Afonso José Celente; Lobo, Suzana Margareth Ajeje.
Rev. bras. ter. intensiva ; 32(1): 17-27, jan.-mar. 2020. tab, graf
Article in English, Portuguese | LILACS | ID: biblio-1138469

ABSTRACT

RESUMO Objetivo: Definir o perfil epidemiológico e os principais determinantes de morbimortalidade dos pacientes cirúrgicos não cardíacos de alto risco no Brasil. Métodos: Estudo prospectivo, observacional e multicêntrico. Todos os pacientes cirúrgicos não cardíacos admitidos nas unidades de terapia intensiva, ou seja, considerados de alto risco, no período de 1 mês, foram avaliados e acompanhados diariamente por, no máximo, 7 dias na unidade de terapia intensiva, para determinação de complicações. As taxas de mortalidade em 28 dias de pós-operatório, na unidade de terapia intensiva e hospitalar foram avaliadas. Resultados: Participaram 29 unidades de terapia intensiva onde foram realizadas cirurgias em 25.500 pacientes, dos quais 904 (3,5%) de alto risco (intervalo de confiança de 95% - IC95% 3,3% - 3,8%), tendo sido incluídos no estudo. Dos pacientes envolvidos, 48,3% eram de unidades de terapia intensiva privadas e 51,7% de públicas. O tempo de internação na unidade de terapia intensiva foi de 2,0 (1,0 - 4,0) dias e hospitalar de 9,5 (5,4 - 18,6) dias. As taxas de complicações foram 29,9% (IC95% 26,4 - 33,7) e mortalidade em 28 dias pós-cirurgia 9,6% (IC95% 7,4 - 12,1). Os fatores independentes de risco para complicações foram Simplified Acute Physiology Score 3 (SAPS 3; razão de chance − RC = 1,02; IC95% 1,01 - 1,03) e Sequential Organ Failure Assessment Score (SOFA) da admissão na unidade de terapia intensiva (RC =1,17; IC95% 1,09 - 1,25), tempo de cirurgia (RC = 1,001; IC95% 1,000 - 1,002) e cirurgias de emergências (RC = 1,93; IC95% 1,10 - 3,38). Em adição, foram associados com mortalidade em 28 dias idade (RC = 1,032; IC95% 1,011 - 1,052) SAPS 3 (RC = 1,041; IC95% 1,107 - 1,279), SOFA (RC = 1,175; IC95% 1,069 - 1,292) e cirurgias emergenciais (RC = 2,509; IC95% 1,040 - 6,051). Conclusão: Pacientes com escores prognósticos mais elevados, idosos, tempo cirúrgico e cirurgias emergenciais estiveram fortemente associados a maior mortalidade em 28 dias e mais complicações durante permanência em unidade de terapia intensiva.


ABSTRACT Objective: To define the epidemiological profile and the main determinants of morbidity and mortality in noncardiac high surgical risk patients in Brazil. Methods: This was a prospective, observational and multicenter study. All noncardiac surgical patients admitted to intensive care units, i.e., those considered high risk, within a 1-month period were evaluated and monitored daily for a maximum of 7 days in the intensive care unit to determine complications. The 28-day postoperative, intensive care unit and hospital mortality rates were evaluated. Results: Twenty-nine intensive care units participated in the study. Surgeries were performed in 25,500 patients, of whom 904 (3.5%) were high-risk (95% confidence interval - 95%CI 3.3% - 3.8%) and were included in the study. Of the participating patients, 48.3% were from private intensive care units, and 51.7% were from public intensive care units. The length of stay in the intensive care unit was 2.0 (1.0 - 4.0) days, and the length of hospital stay was 9.5 (5.4 - 18.6) days. The complication rate was 29.9% (95%CI 26.4 - 33.7), and the 28-day postoperative mortality rate was 9.6% (95%CI 7.4 - 12.1). The independent risk factors for complications were the Simplified Acute Physiology Score 3 (SAPS 3; odds ratio - OR = 1.02; 95%CI 1.01 - 1.03) and Sequential Organ Failure Assessment Score (SOFA) on admission to the intensive care unit (OR = 1.17; 95%CI 1.09 - 1.25), surgical time (OR = 1.001, 95%CI 1.000 - 1.002) and emergency surgeries (OR = 1.93, 95%CI, 1.10 - 3.38). In addition, there were associations with 28-day mortality (OR = 1.032; 95%CI 1.011 - 1.052), SAPS 3 (OR = 1.041; 95%CI 1.107 - 1.279), SOFA (OR = 1.175, 95%CI 1.069 - 1.292) and emergency surgeries (OR = 2.509; 95%CI 1.040 - 6.051). Conclusion: Higher prognostic scores, elderly patients, longer surgical times and emergency surgeries were strongly associated with higher 28-day mortality and more complications during the intensive care unit stay.


Subject(s)
Humans , Male , Female , Adult , Middle Aged , Aged , Postoperative Complications/epidemiology , Hospital Mortality , Brazil , Prospective Studies , Risk Assessment , Intensive Care Units
SELECTION OF CITATIONS
SEARCH DETAIL